08.12.09 19:02 Age: 95 days
IPSOGEN strengthens its Management and Board of Directors
Category: Corporate, Investors
Marseille, 8th December 2009 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company that develops, manufactures and markets tests for leukemia and breast cancer, today announces changes in its board and management team with the goal of providing increased management focus to execute its strategic plan.
- Gilles Alberici, PhD, who joined the company’s Board of Directors in 2007, has been elected non executive Chairman of the Board.
- Susan Hertzberg, MBA, currently President of Ipsogen Inc and VP Corporate Development is nominated CEO of Ipsogen US subsidiary.
- Pascale Boissel has been appointed Chief Financial Officer and member of Ipsogen Executive Committee to lead the financial department of Ipsogen.
“These changes reflect the ambition of Ipsogen and its executive management team in strongly supporting the business opportunities we see in the US for cancer molecular diagnostic testing services and in Europe and Asia for cancer molecular diagnostic products. Gilles has been of tremendous help in the past two years as board member and I will increasingly rely on him to bring to reality the strategic vision of the company. Susan demonstrated an exceptional ability to execute our business plan in the US and I am confident that her new position will further help the company to reach the next level. We are also pleased to welcome Pascale, her strong experience in corporate finance at an international level will be of major importance in helping the team to drive our growth” said Vincent Fert, Chief Executive of Ipsogen.
More
